Medical Marijuana, Inc. Subsidiary HempMeds® Brasil To Hold Its Second Doctor Symposium on Medical Cannabis in Sao Paulo, Brazil

Sold-Out Event to Educate Brazilian Medical Community on Therapeutic Uses of Cannabis, Importation and Prescribing Rules to Provide Patients Greater Access

SAN DIEGOAug. 14, 2017 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil is holding a sold-out doctor symposium in Sao Paulo, Brazil, dedicated to providing the Brazilian medical community with information about the medical value of cannabidiol (CBD), how to legally import CBD into the country and prescribe it for patients and present CBD clinical study results.

The symposium, which will take place at the Renaissance Hotel in Sao Paulo on August 15, is part of the Company’s goal to educate health professionals on the therapeutic uses of cannabis and will feature renowned medical experts and pioneers in the field like Dr. Saul Garza Morales, pediatric researcher and neurologist in Mexico, and Dr. Stuart Titus, Chief Executive Officer of Medical Marijuana, Inc. Both will share on the specific therapeutic benefits of CBD, as well as gaining access to medical cannabis for improving health and quality of life.

Dr. Garza will also share the positive results of a recent study he conducted on the effects of Medical Marijuana, Inc.’s Real Scientific Hemp Oil-X™ (RSHO-X™) product in treating children with severe epilepsy, in which 86 percent of the 29 patients he studied experienced statistically significant (greater than 50%) reduction in motor seizures. Seventeen percent of the children were fully seizure free for a 4-month period.

“We are encouraged that this second doctor symposium that we are holding in Brazil is completely sold out, which means health professionals throughout the Country are becoming increasingly interested in how they can prescribe CBD hemp oil products to their patients and learn about the plethora of benefits that medical cannabis provides to treat several types of indications,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We look forward to continuing educating and working with Brazilian doctors to strengthen the lives and livelihoods of those in Brazil who suffer needlessly in silence and to provide additional research on the therapeutic benefits of botanical CBD.”

HempMeds Brasil™ is the first company to offer legal medicinal cannabis products to Brazil after receiving import approval to those suffering from specific medical conditions. Most recently in February 2017, for the filling of a prescription for the first time for the Company’s hemp CBD oil product RSHO™ to treat patients in the Country suffering from Multiple Sclerosis. Additionally, doctors in Brazil can prescribe RSHO™ for any condition and HempMeds Brasil™ has worked with several cases including patients suffering from:

  • Epilepsy
  • Psoriasis
  • Pain
  • Cancer
  • Parkinson’s
  • Alzheimer’s
  • Migraine
  • Diabetes
  • Amyotrophic Lateral Sclerosis

About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically-sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About HempMeds® Brasil 
HempMeds® Brasil currently has three cannabis products approved for importation into Brazil as a prescription medication for multiple conditions including; Epilepsy, Parkinson’s, Chronic Pain, Psoriasis, Cancer, Alzheimer’s, Diabetes, ALS, Multiple Sclerosis and Migraines. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds® Brasil is working on additional approvals for multiple indications.

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties. The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
[email protected]